Role of surgical staging and adjuvant treatment in uterine serous carcinoma
This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence. Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared. Of the 51 patients...
Gespeichert in:
| Veröffentlicht in: | European journal of gynaecological oncology 2013, Vol.34 (5), p.453-456 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 456 |
|---|---|
| container_issue | 5 |
| container_start_page | 453 |
| container_title | European journal of gynaecological oncology |
| container_volume | 34 |
| creator | Frey, M K Bashir, S Ward, N M Hensel, K J Caputo, T A Holcomb, K M Baergen, R Gupta, D |
| description | This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence.
Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared.
Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043).
In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1493796814</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1493796814</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-864fbd56a01ea8d21f1adb53a1cc864ce8fca19b3c381c1bc747c71226458a7a3</originalsourceid><addsrcrecordid>eNo1kE1LxDAYhHNQ3HX1L0iOXgrNR5P0KItfuCCInsvb5G3J0qY1SQX_vQV3TzMwD8MwF2RbipoXvBZqQ65TOpallFrxK7Lhq6kqw7fk7WMakE4dTUvsvYWBpgy9Dz2F4Ci44_IDIdMcEfKIq_OBLhmjD0gTxmlJ1EK0Pkwj3JDLDoaEtyfdka-nx8_9S3F4f37dPxyKmTOWC6Nk17pKQckQjOOsY-DaSgCzds0sms4Cq1thhWGWtVZLbTXjXMnKgAaxI_f_vXOcvhdMuRl9sjgMEHAd1DBZC10rw-SK3p3QpR3RNXP0I8Tf5nyA-AMGPVbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1493796814</pqid></control><display><type>article</type><title>Role of surgical staging and adjuvant treatment in uterine serous carcinoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Frey, M K ; Bashir, S ; Ward, N M ; Hensel, K J ; Caputo, T A ; Holcomb, K M ; Baergen, R ; Gupta, D</creator><creatorcontrib>Frey, M K ; Bashir, S ; Ward, N M ; Hensel, K J ; Caputo, T A ; Holcomb, K M ; Baergen, R ; Gupta, D</creatorcontrib><description>This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence.
Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared.
Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043).
In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.</description><identifier>ISSN: 0392-2936</identifier><identifier>PMID: 24475582</identifier><language>eng</language><publisher>Italy</publisher><subject>Aged ; Chemotherapy, Adjuvant ; Cystadenocarcinoma, Serous - mortality ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - therapy ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Retrospective Studies ; Uterine Neoplasms - mortality ; Uterine Neoplasms - pathology ; Uterine Neoplasms - therapy</subject><ispartof>European journal of gynaecological oncology, 2013, Vol.34 (5), p.453-456</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,4025</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24475582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frey, M K</creatorcontrib><creatorcontrib>Bashir, S</creatorcontrib><creatorcontrib>Ward, N M</creatorcontrib><creatorcontrib>Hensel, K J</creatorcontrib><creatorcontrib>Caputo, T A</creatorcontrib><creatorcontrib>Holcomb, K M</creatorcontrib><creatorcontrib>Baergen, R</creatorcontrib><creatorcontrib>Gupta, D</creatorcontrib><title>Role of surgical staging and adjuvant treatment in uterine serous carcinoma</title><title>European journal of gynaecological oncology</title><addtitle>Eur J Gynaecol Oncol</addtitle><description>This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence.
Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared.
Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043).
In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.</description><subject>Aged</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cystadenocarcinoma, Serous - mortality</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Retrospective Studies</subject><subject>Uterine Neoplasms - mortality</subject><subject>Uterine Neoplasms - pathology</subject><subject>Uterine Neoplasms - therapy</subject><issn>0392-2936</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LxDAYhHNQ3HX1L0iOXgrNR5P0KItfuCCInsvb5G3J0qY1SQX_vQV3TzMwD8MwF2RbipoXvBZqQ65TOpallFrxK7Lhq6kqw7fk7WMakE4dTUvsvYWBpgy9Dz2F4Ci44_IDIdMcEfKIq_OBLhmjD0gTxmlJ1EK0Pkwj3JDLDoaEtyfdka-nx8_9S3F4f37dPxyKmTOWC6Nk17pKQckQjOOsY-DaSgCzds0sms4Cq1thhWGWtVZLbTXjXMnKgAaxI_f_vXOcvhdMuRl9sjgMEHAd1DBZC10rw-SK3p3QpR3RNXP0I8Tf5nyA-AMGPVbw</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Frey, M K</creator><creator>Bashir, S</creator><creator>Ward, N M</creator><creator>Hensel, K J</creator><creator>Caputo, T A</creator><creator>Holcomb, K M</creator><creator>Baergen, R</creator><creator>Gupta, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2013</creationdate><title>Role of surgical staging and adjuvant treatment in uterine serous carcinoma</title><author>Frey, M K ; Bashir, S ; Ward, N M ; Hensel, K J ; Caputo, T A ; Holcomb, K M ; Baergen, R ; Gupta, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-864fbd56a01ea8d21f1adb53a1cc864ce8fca19b3c381c1bc747c71226458a7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cystadenocarcinoma, Serous - mortality</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Retrospective Studies</topic><topic>Uterine Neoplasms - mortality</topic><topic>Uterine Neoplasms - pathology</topic><topic>Uterine Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frey, M K</creatorcontrib><creatorcontrib>Bashir, S</creatorcontrib><creatorcontrib>Ward, N M</creatorcontrib><creatorcontrib>Hensel, K J</creatorcontrib><creatorcontrib>Caputo, T A</creatorcontrib><creatorcontrib>Holcomb, K M</creatorcontrib><creatorcontrib>Baergen, R</creatorcontrib><creatorcontrib>Gupta, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of gynaecological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frey, M K</au><au>Bashir, S</au><au>Ward, N M</au><au>Hensel, K J</au><au>Caputo, T A</au><au>Holcomb, K M</au><au>Baergen, R</au><au>Gupta, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of surgical staging and adjuvant treatment in uterine serous carcinoma</atitle><jtitle>European journal of gynaecological oncology</jtitle><addtitle>Eur J Gynaecol Oncol</addtitle><date>2013</date><risdate>2013</risdate><volume>34</volume><issue>5</issue><spage>453</spage><epage>456</epage><pages>453-456</pages><issn>0392-2936</issn><abstract>This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence.
Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared.
Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043).
In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.</abstract><cop>Italy</cop><pmid>24475582</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-2936 |
| ispartof | European journal of gynaecological oncology, 2013, Vol.34 (5), p.453-456 |
| issn | 0392-2936 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1493796814 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Chemotherapy, Adjuvant Cystadenocarcinoma, Serous - mortality Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - therapy Female Humans Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Retrospective Studies Uterine Neoplasms - mortality Uterine Neoplasms - pathology Uterine Neoplasms - therapy |
| title | Role of surgical staging and adjuvant treatment in uterine serous carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T03%3A55%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20surgical%20staging%20and%20adjuvant%20treatment%20in%20uterine%20serous%20carcinoma&rft.jtitle=European%20journal%20of%20gynaecological%20oncology&rft.au=Frey,%20M%20K&rft.date=2013&rft.volume=34&rft.issue=5&rft.spage=453&rft.epage=456&rft.pages=453-456&rft.issn=0392-2936&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1493796814%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1493796814&rft_id=info:pmid/24475582&rfr_iscdi=true |